Tislelizumab plus chemo for MHC-II-positive stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a drug called tislelizumab (an immunotherapy) to standard chemotherapy before and after surgery is better than chemotherapy alone for people with a specific type of stomach or GEJ cancer that has a high level of a marker called MHC class II. The goal is to see if it helps shrink the tumor and improves the chance of successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is a type of stomach or gastroesophageal junction (GEJ) adenocarcinoma (confirmed by biopsy).
- Your tumor must have a specific marker (MHC class II) that is 2+ or 3+ on a test (you can ask your doctor about this).
- Your cancer is locally advanced (spread to nearby lymph nodes but not to other organs) and you have not had any prior treatment.
- You are able to swallow pills and are in generally good health (ECOG score 0 or 1).
- You have adequate blood counts, liver, and kidney function (tests can confirm).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy before and after surgery can help treat stomach or gastroesophageal junction cancer. It is for people whose cancer has not spread to other organs and who are well enough to have surgery.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This study tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy (SOX) as a first treatment for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this combination can help shrink the tumor before surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) and chemotherapy after surgery to prevent stomach cancer from coming back in older patients. It may be a good option for people who have had their cancer completely removed and are in good overall health.
This Phase 2 trial studies giving tislelizumab (an immune therapy) together with pre-surgery chemoradiation for locally advanced stomach or GEJ (esophagus-stomach junction) adenocarcinoma. It compares this approach to the standard treatment (chemoradiation plus surgery) to see if it improves outcomes.
Hear when a new Gastric Cancer Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.